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Dear Sir,
In a famous Swedish cartoon from the mid-1980s (Staffans
Stollar), two men have a discussion in which one states:
“Life is so dangerous that it is strange that the National
Board of Health & Welfare allows it!” This cartoon
encapsulates our perceptions of the risk-benefit analysis of
certain regulations in experimental medicine, particularly as
they pertain to the development of new molecular imaging
tracers.
From a social point of view, risk aversion is a prominent
human trait, but one which is not always rational or guided
by statistical support. Today, in medical science, we
demand an evidence-based approach that is both well-
informed and logical. So how do we handle and interpret
absolute risks in exploratory medical research and how
should we compare it with other risks? There is a strong
tendency to exaggerate immediate and acute risks and
downplay the associated potential long-term benefits.
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Although the FDA in their ground-breaking “Critical Path
Initiative” points to the need for more exploratory studies
in humans, the existing dogma followed by most
regulatory bodies is to avoid all potential risks if benefits
are difficult to assess in the short term. This may seem
to be a wise strategy; however, it is perceived by many
of us as leading to stagnation in clinical research and
missed opportunities to gain new knowledge in the
complex biology of man. Benefits are not always easy
to predict. However, if the foreseeable risk is small (with
a certain probability), potential benefits must be put into
the equation! Current PET technology utilizes radio-
nuclides in minute (homeopathic) doses, but with high
specific radioactivity. It is actually implicit in the broad
acceptance of the “microdosing” concept advocated for
the development of therapeutic agents that such tiny
chemical quantities are likely to be safe.
Moreover, the radiation exposure is low, generally being
comparable to that obtained from 1 year of natural
background radiation. Despite these considerations, a new
PET tracer being used in early clinical development and
planned for use in perhaps only a handful of patients is,
from a regulatory perspective, viewed as a new drug in
many parts of the world. In Europe, in particular, new PET
tracers are required to undergo full GMP qualification of its
production. While new “microdosing” guidelines have
simplified toxicological evaluation and represent a signif-
icant step forward, European guidelines still require
traditional genotoxicity tests, although the human exposure
to a PET tracer might be many 1,000-fold lower than that
from traditional drugs. Almost the same requirements are
put on the production of a PET tracer that will be tested in
only a few individuals as on the production of new
therapeutic drugs that will potentially be used in long-
term clinical trials involving thousands of patients. Clearly,
the risks to society are dramatically different!
We care deeply about progress in medicine and are
vitally concerned for the safety of our current volunteers
and patients, while at the same time trusting that novel
scientific knowledge can bring benefits to future patients.
Therefore, we argue that there is an urgent need for a joint
effort to reduce hurdles to radiotracer development and
provide a better balance between the regulatory actions
aimed at diminishing risk and fostering early human studies
that can benefit science. Our intention as scientists in the
medical field is never to harm but to strive to help and to
support society by combating disease. In this we do not
need hindrance, but support from public and private
regulatory bodies. Let’s do this together!
We end this note with a slightly modified quotation by
Albert Einstein: “The world is dangerous to live in, not
because of those who do evil (hinder), but because of those
who look on and let them do so.”
Uppsala, 7 April 2009
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